bevyxxa Drug Patent Profile
✉ Email this page to a colleague
When do Bevyxxa patents expire, and what generic alternatives are available?
Bevyxxa is a drug marketed by Portola Pharms Inc and is included in one NDA. There are five patents protecting this drug.
This drug has sixty-seven patent family members in twenty-six countries.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
DrugPatentWatch® Generic Entry Outlook for Bevyxxa
Bevyxxa was eligible for patent challenges on June 23, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 29, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for bevyxxa?
- What are the global sales for bevyxxa?
- What is Average Wholesale Price for bevyxxa?
Summary for bevyxxa
International Patents: | 67 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 84 |
Patent Applications: | 420 |
Drug Prices: | Drug price information for bevyxxa |
DailyMed Link: | bevyxxa at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bevyxxa
Generic Entry Date for bevyxxa*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for bevyxxa
bevyxxa is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of bevyxxa is ⤷ Subscribe.
This potential generic entry date is based on patent ⤷ Subscribe.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for bevyxxa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | ⤷ Subscribe | ⤷ Subscribe |
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | ⤷ Subscribe | ⤷ Subscribe |
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | ⤷ Subscribe | ⤷ Subscribe |
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | ⤷ Subscribe | ⤷ Subscribe |
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for bevyxxa
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Portola Pharma UK Limited | Dexxience | betrixaban | EMEA/H/C/004309 Prevention of venous thromboembolism |
Refused | no | no | no | 2018-09-20 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for bevyxxa
When does loss-of-exclusivity occur for bevyxxa?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 07333377
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Estimated Expiration: ⤷ Subscribe
Canada
Patent: 71502
Patent: FORMULATIONS DE DOSES UNITAIRES ET PROCEDES DE TRAITEMENT D'UNE THROMBOSE AVEC UN INHIBITEUR ORAL DU FACTEUR XA (UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR)
Estimated Expiration: ⤷ Subscribe
Patent: 13963
Patent: FORMULATIONS DE DOSES UNITAIRES ET PROCEDES DE TRAITEMENT D'UNE THROMBOSE AVEC UN INHIBITEUR ORAL DU FACTEUR XA (UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR)
Estimated Expiration: ⤷ Subscribe
China
Patent: 1652136
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor XA inhibitor
Estimated Expiration: ⤷ Subscribe
Patent: 5193799
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Estimated Expiration: ⤷ Subscribe
Colombia
Patent: 20933
Patent: FORMULACIONES DE DOSIS UNITARIA Y METDODS PARA EL TRATAMIENTO DE LA TROMBOSIS CON UN INHIBIDOR ORAL DEL FACROR XA
Estimated Expiration: ⤷ Subscribe
Costa Rica
Patent: 914
Patent: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR
Estimated Expiration: ⤷ Subscribe
Ecuador
Patent: 099501
Patent: FORMULACIONES DE DOSIS UNITARIA Y MÉTODOS PARA EL TRATAMIENTO DE LA TROMBOSIS CON UN INHIBIDOR ORAL DEL FACTOR XA
Estimated Expiration: ⤷ Subscribe
European Patent Office
Patent: 01760
Patent: FORMULATIONS DE DOSES UNITAIRES ET PROCÉDÉS DE TRAITEMENT D'UNE THROMBOSE AVEC UN INHIBITEUR ORAL DU FACTEUR XA (UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR)
Estimated Expiration: ⤷ Subscribe
Hong Kong
Patent: 34031
Patent: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR
Estimated Expiration: ⤷ Subscribe
Israel
Patent: 9219
Patent: בטריקסאבאן או מלחיו, לשימוש בעיכוב קרישת דם (Betrixaban or salt thereof for use in inhibiting blood coagulation)
Estimated Expiration: ⤷ Subscribe
Morocco
Patent: 086
Patent: FORMULATIONS DE DOSES UNITAIRES ET PROCEDES DE TRAITEMENT D'UNE THROMBOSE AVEC UN INHIBITEUR ORAL DU FACTEUR XA.
Estimated Expiration: ⤷ Subscribe
New Zealand
Patent: 8180
Patent: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR
Estimated Expiration: ⤷ Subscribe
Nicaragua
Patent: 0900145
Patent: FORMULACIONES DE DOSIS UNITARIA Y METODOS PARA EL TRATAMIENTO DE LA TROMBOSIS CON UN INHIBIDOR ORAL DEL FACTOR XA.
Estimated Expiration: ⤷ Subscribe
Portugal
Patent: 01760
Estimated Expiration: ⤷ Subscribe
Russian Federation
Patent: 52484
Patent: СТАНДАРТНЫЕ ЛЕКАРСТВЕННЫЕ ПРЕПАРАТЫ И СПОСОБЫ ЛЕЧЕНИЯ ТРОМБОЗА ПЕРОРАЛЬНЫМ ВВЕДЕНИЕМ ИНГИБИТОРА ФАКТОРА ХА (STANDARD DRUG PREPARATIONS AND METHODS OF TREATING THROMBOSIS BY ORAL ADMINISTRATION OF FACTOR XA INHIBITOR)
Estimated Expiration: ⤷ Subscribe
Patent: 09126147
Patent: СТАНДАРТНЫЕ ЛЕКАРСТВЕННЫЕ ПРЕПАРАТЫ И СПОСОБЫ ЛЕЧЕНИЯ ТРОМБОЗА ПЕРОРАЛЬНЫМ ВВЕДЕНИЕМ ИНГИБИТОРА ФАКТОРА Ха
Estimated Expiration: ⤷ Subscribe
Patent: 12104816
Patent: СТАНДАРТНЫЕ ЛЕКАРСТВЕННЫЕ ПРЕПАРАТЫ И СПОСОБЫ ЛЕЧЕНИЯ ТРОМБОЗА ПЕРОРАЛЬНЫМ ВВЕДЕНИЕМ ИНГИБИТОРА ФАКТОРА ХА
Estimated Expiration: ⤷ Subscribe
Singapore
Patent: 201504425S
Patent: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR
Estimated Expiration: ⤷ Subscribe
South Africa
Patent: 0904758
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
Estimated Expiration: ⤷ Subscribe
South Korea
Patent: 1472765
Estimated Expiration: ⤷ Subscribe
Patent: 090107499
Patent: Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Estimated Expiration: ⤷ Subscribe
Spain
Patent: 09090
Estimated Expiration: ⤷ Subscribe
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering bevyxxa around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2002110295 | ⤷ Subscribe | |
South Africa | 200202117 | Inhibitors of factor Xa. | ⤷ Subscribe |
Mexico | 226123 | BENZAMIDAS E INHIBIDORES DEL FACTOR XA RELACIONADAS. (BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa.) | ⤷ Subscribe |
Norway | 20021229 | ⤷ Subscribe | |
World Intellectual Property Organization (WIPO) | 0164642 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Bevyxxa Market Analysis and Financial Projection Experimental
More… ↓